Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 3/20 | 0.41 |
| ▸ | MC5R | P33032 | 3/20 | 0.41 |
| ▸ | MC3R | P41968 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415523 | 0.94 | CCR6 (0.54) | CCR6PAX8LTA4HMMP2MC4R | |
| SCHEMBL759516 | 0.87 | CCR6 (0.66) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL7535687 | 0.85 | CCR6 (0.64) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL20335061 | 0.85 | LTA4H (0.52) | LTA4HMMP2ANPEPIDO1DPP8 | |
| SCHEMBL4622400 | 0.85 | LTA4H (0.52) | LTA4HMMP2ANPEPIDO1DPP8 | |
| Hydrochloric Acid SCHEMBL547894 | 0.84 | LTA4H (0.51) | LTA4HMMP2ANPEPIDO1DPP8 | |
| SCHEMBL676143 | 0.84 | LTA4H (0.57) | LTA4HMMP2ANPEPIDO1DPP8 | |
| SCHEMBL730307 | 0.84 | LTA4H (0.57) | LTA4HMMP2ANPEPIDO1DPP8 | |
| SCHEMBL417986 | 0.83 | CCR6 (0.53) | CCR6PAX8LTA4HANPEPIDO1 | |
| SCHEMBL27944748 | 0.83 | CCR6 (0.53) | CCR6PAX8LTA4HANPEPIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664409-B2 | Process for the preparation of (poly) aminoalkylaminoacetamide derivatives of epipodophyllotoxin useful for their applications in therapeutics as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PTMA, NPEPPS, DNPEP | CCR6 3824/4885PAX8 2180/4885LTA4H 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.